The European Investment Bank (EIB) is providing Innsbruck-based biotech firm Innovacell with a venture debt loan of up to €15 million to finance its €40 million investment plan over the next three years. The Austrian biotech company develops innovative autologous cell therapies for treating faecal and urinary incontinence. These diseases affect many people, especially those of older age.
These are some of the results from the latest release of the 2021-2022 Climate Survey conducted in September 2021 and published today by the European Investment Bank (EIB). The EIB is the lending arm of the European Union and the world’s largest multilateral lender for climate action projects.
The second part of the 2021-2022 EIB Climate Survey explores people’s views on climate change in a rapidly changing world. The results from this release focus on citizens’ individual behaviour and the actions they are taking to combat climate change.